Quantum Genomics to announce Phase IIa clinical trial results for high blood pressure on September 29, 2016 | Bourse Reflex
Accueil > Actualités > Communiqués

€ 6.4  -2.59%
AJOUTER À : Mon Portefeuille | Ma Liste | Mes alertes

Quantum Genomics to announce Phase IIa clinical trial results for high blood pressure on September 29, 2016

Lundi 12 Sep 2016 à 18:00

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it will release the results of the Phase IIa clinical trial for high blood pressure (QGC001 program) on September 29, 2016, after the close of Euronext Paris

As a reminder, this clinical trial evaluated around 30 patients with high blood pressure at four clinical investigation centres in France, under the supervision of Prof. Michel Azizi, Clinical Investigation Centre at Georges Pompidou European Hospital, Paris. It was a randomised, double-blinded study, with cross-over, to compare the effects of the product QGC001 (500 mg morning and night) with those of a placebo. It also aimed to analyse the pharmacodynamic effects of QGC001 on several hormonal biomarkers.

 


ABOUT QUANTUM GENOMICS

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.

Quantum Genomics is listed on the Alternext market in Paris (isin code FR0011648971, Ticker ALQGC).

The Company has offices in Paris, France and New York, NY, USA. For more information, please visit www.quantum-genomics.com.

Twitter : @ALQGC_EN LinkedIn : Quantum Genomics


CONTACTS

Quantum Genomics
Lionel Ségard
Chairman & Chief Executive Officer
+33 1 85 34 77 77
Quantum Genomics
Marc Karako
CFO – Investor Relations
+33 1 85 34 77 75
marc.karako@quantum-genomics.com
ACTUS finance et communication (Europe) Jean-Michel Marmillon
Press Relations
+33 1 53 67 36 73
jmmarmillon@actus.fr
The Ruth Group (U.S.)
Lee Roth / Kirsten Thomas
Investor / Public Relations
+1 646-536-7012 / +1 508-280-6592


Partager sur Facebook
Article Précédent :
INFORMATION MENSUELLE RELATIVE AUX...
Article Suivant :
Résultats semestriels 2016

Ecrire un commentaire

J'accepte la charte et que mon commentaire soit publié sur BourseReflex.com 

Les autres actualités


Retour vers 'Communiqués' »




Mots-clés : New york   Usa   Genomics   Clinical   Blood   Alqgc   Developing   Unmet   Field  
Sociétés citées dans cette news : QUANTUM GENOMICS   Quantum Genomics   Euronext  

Si vous passez un ordre de bourse sur le CAC40 le vendredi soir à 18h, quand sera t-il éxécuté?
Mon portefeuille virtuel

Initiez-vous à la gestion gratuitement et sans risque !

Ma liste de valeurs

Suivez l'évolution du cours de vos valeurs préférées !

Alerte email

Soyez immediatement informés


Retrait de Borloo
Jean-Louis Borloo a décidé de ne pas se porter candidat à l'élection présidentielle de 2012. Qu'en pensez-vous?